Needham & Co Comments On Geron (GERN) After GE Healthcare News
More News related to GERN
- Notable Analyst Rating Changes 11/02: MOT, UFS, GNW, EL, JWN, WY, RCL, CS Upgraded; RIMM, PALM, CMCSA, ERJ, GERN Downgraded
- Needham & Co Downgrades Geron Corporation (GERN) to Hold
- Needham Downgrades Geron (GERN) to Hold
- Merriman Curhan Ford Reiterates 'Buy' Geron Corporation (GERN); Important Stem Cell Visibility
- Geron (GERN) Announces Plan to Advance Clinical Development of Stem Cell Product; Will Enable Reinitiation of Phase I Trial
Analysts at Needham & Co commented on this morning's market mover Geron Corporation (Nasdaq: GERN) (+18%) after the company announced a global exclusive license aggreement with GE Healthcare to develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and toxicity screening.
Needham said with the financial terms not disclosed they expect the terms to be "modest," but notes the value of the opportunity lies in the quality of the partner as well as the efforts of the Company to leverage its ESC technology platform.
Given the expected upcoming Phase 1 trial initiation for the GRNOPC1 program as well as anticipated progress in other Geron programs, Needham reiterates their BUY rating and $9 price target.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Analyst CommentsMomentum Movers
Stocks Mentioned
+0.02Related Entities
Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
GERON
RICHARD TEAGUE on Jun 30, 2009 12:19 PMThanks for the info!